Annual report pursuant to Section 13 and 15(d)

Related Party Transactions (Details Narrative)

v3.20.1
Related Party Transactions (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Jul. 04, 2018
Nov. 30, 2019
Jul. 31, 2019
Jun. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Dr. Zumeris and Janina Zumeris [Member] | Separation and Release Agreement [Member]            
Sale stock price per share $ 4.45          
Consulting payments $ 18          
Value of cash received $ 950          
Description of payment term In addition, if the Company (i) grants a license for the skin rejuvenation technology, then the Company will pay Dr. Zumeris 10% from the payments received by the Company until an aggregate amount of $100,000 has been paid to Dr. Zumeris, (ii) sells the skin rejuvenation technology and/or the rights to such as a standalone product, the Company will pay Dr. Zumeris $100 from the proceeds of such sale, or (iii) sells the skin rejuvenation devices, the Company will pay Dr. Zumeris $5 per unit an aggregate amount of $100 has been paid to Dr. Zumeris.          
Exercise price of options           $ 4.45
Costs and expense           $ 108
Common Stock [Member]            
Number of common stock exchanged into preferred stock         275,000 250,000
Common Stock [Member] | Board Member [Member]            
Number of shares sold   25,000        
Value of shares sold   $ 50        
Sale stock price per share   $ 2        
Series C Preferred Stock [Member]            
Number of common stock exchanged into preferred stock         250,000 250,000
Series E Preferred Stock [Member]            
Number of common stock exchanged into preferred stock         15,000  
Series E Preferred Stock [Member] | Existing Shareholders [Member]            
Number of shares sold     1,810,000 1,810,000    
Value of shares sold     $ 3,620 $ 3,620    
Sale stock price per share     $ 2.00 $ 2.00